The life-sciences industry is a jewel in Britain’s economy
Policymakers can do more to help it sparkle
Tree-lined lawns and historic buildings provide the backdrop for high-tech wizardry at the Babraham Research Campus in Cambridge. Alchemab, a three-year-old company housed in its laboratories, is built on the idea that a person’s response to chronic diseases may stem from differences in the antibodies they produce. Jane Osbourn, the firm’s chief scientist, says they have already found a set of antibodies common to survivors of pancreatic cancer. The firm raised £60m ($82m) in 2021 on the back of such discoveries.
This article appeared in the Britain section of the print edition under the headline “Bio Britannia”
Britain July 23rd 2022
- The life-sciences industry is a jewel in Britain’s economy
- Haleon’s listing shows the problems afflicting the London Stock Exchange
- Rishi Sunak and Liz Truss will battle to be Britain’s next prime minister
- The Tories seem to be cooling on Boris Johnson’s signature policy
- A superhighway for drones to fly between British cities
- The choice between Rishi Sunak and Liz Truss
From the July 23rd 2022 edition
Discover stories from this section and more in the list of contents
Explore the editionMore from Britain
Britain’s brokers are diversifying and becoming less British
London’s depleted stockmarket is forcing them to change
What a buzzy startup reveals about Britain’s biotech sector
Lots of clever scientists, not enough business nous
Britain’s government lacks a clear Europe policy
It should be more ambitious over getting closer to the EU
The Rachel Reeves theory of growth
The chancellor says it’s her number-one priority. We ask her what that means for Britain